OS Therapies Incorporated

AMEX:OSTX

Biotechnology

Healthcare
$1.15 +5.81%

+$0.10 today

Market cap
$53.83M
Beta
-0.95
P/E (TTM)
-2.0
EPS (TTM)
-$0.91
52W Low $1.15High $2.57

Volume 0.50M

Average 0.71M

OSTX Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

OS Therapies IncorporatedAMEX: OSTX

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin dips below year-ago levels

Q1 FY2026 selling, general & admin of $2.82M fell 23.7% year over year, behind the +166786.7% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at +2103.6% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 3 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +310482.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.82M-100.0% QoQ
Last fiscal yearDec 2025
$12.34B+310482.2% YoY
LTMMar 2026
$12.34B+166786.7% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.7%-100.0%-76.3 pp
1 year+310482.2%-100.0%-310582.2 pp
3-year CAGR+2103.6%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
12.34B USD
Year-over-year change
+310482.2%
4-year CAGR
+851.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How OSTX compares with its peers on the latest reported figures

  • OSTX's LTM Mar 2026 selling, general & admin of $12.34B is the highest of the 9 companies compared; the peer median is $15.75M.
  • Its year-over-year change of +166786.7% is the 2nd highest of 8, against a peer median of +4.7%.
  • Over three fiscal years its annual growth of +2103.6% compares with a peer median of -12.1%.
OSTX Competitors Peer median
Selling, General & Admin for OSTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OSTXOS Therapies IncorporatedLTM Mar 2026$12.34B +166786.7%+2103.6%—
INKTMiNK Therapeutics, Inc.LTM Mar 2026$8.41B +205316.4%+855.6%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$38.12M -1.4%+24.4%11443.7%
HOWLWerewolf Therapeutics, Inc.LTM Jun 2026$19.35M +4.7%-9.7%92.1%
SPRBSpruce Biosciences, Inc.LTM Mar 2026$17.75M +26.9%+12.0%—
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$13.76M +12.8%-21.8%600.0%
EQEquillium, Inc.LTM Mar 2026$10.46M -6.1%-14.5%—
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$8.86M +3.4%-29.6%626.3%
ADAGAdagene Inc.LTM Jun 2024$7.81M —-15.8%957.8%
Peer median (excluding OSTX) $15.75M+4.7%-12.1%626.3%

Competitors are the stored peer set for OSTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue1.16M8054.22K2.78K363.09K
Gross Profit(1.16M)(805)(4.22K)(2.78K)(363.09K)
Gross Margin—————
Research & Development2.17M3.29M3.22M2.84M16.36B
Selling, General & Admin1.5M1.15M1.12M3.97M12.34B
Operating Expenses3.68M4.45M4.34M6.81M28.34M
Depreciation & Amortization8058054.22K2.78K363.09K
EBITDA(4.84M)(4.45M)(4.34M)(6.83M)(28.39M)
EBITDA Margin—————
Operating Income(4.84M)(4.45M)(4.34M)(6.81M)(28.71M)
Operating Margin—————
Interest Income0000249
Interest Expense2.58M1.81M3.45M2.05M0
Other Income / Expenses(2.58M)(1.81M)(3.45M)(2.07M)(48.14K)
Income Before Tax(7.42M)(6.25M)(7.79M)(8.88M)(28.75M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(7.42M)(6.25M)(7.79M)(8.88M)(28.75M)
Net Margin—————
EPS (Basic)(0.33)(0.28)(0.39)(0.52)(0.98)
EPS (Diluted)(0.33)(0.28)(0.39)(0.52)(0.98)
Weighted Avg Shares23.1M23.1M20.05M20.87M29.25M
Weighted Avg Shares (Diluted)23.1M23.1M20.05M20.87M29.25M

OS Therapies Incorporated

AMEX:OSTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.